Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
38 hedge funds and large institutions have $21M invested in Oncternal Therapeutics, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 5 reducing their positions, and 2 closing their positions.
180% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 5
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
117% more capital invested
Capital invested by funds: $9.68M → $21M (+$11.4M)
23% more call options, than puts
Call options by funds: $53K | Put options by funds: $43K
9% more funds holding
Funds holding: 35 → 38 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$92.4K |
| 2 |
Nomura Holdings
Tokyo,
Japan
|
+$72.5K |
| 3 |
Morgan Stanley
New York
|
+$46.9K |
| 4 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
+$45.5K |
| 5 |
D.E. Shaw & Co
New York
|
+$42.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$344K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$42K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$18.5K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$18.5K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$8.53K |
ONCT Hedge Fund Activity: Q2 2015 in Review
38 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q2 2015, worth a combined $21M — up 117% from $9.68M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ONCT positions and 2 closed out — a net gain of 3 holders — while 14 added to existing stakes and 5 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $92.4K. The largest seller was BVF Inc, cutting an estimated $344K.
- 38 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q2 2015, up from 35 in Q1 2015.
- Funds reported $21M of Oncternal Therapeutics, Inc. Common Stock stock for Q2 2015, up 117% quarter-over-quarter.
- 5 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q2 2015 and 2 closed out, a net change of +3 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q2 2015 was BlackRock Fund Advisors, an estimated $92.4K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q2 2015 was BVF Inc, an estimated $344K sold.
Based on aggregated 13F filings for Q2 2015.